A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)

The main purpose of this study is to evaluate the efficacy and safety of orforglipron on maintenance of body weight reduction in participants who previously completed treatment with injectable tirzepatide (Zepbound) or injectable semaglutide (Wegovy) in the SURMOUNT-5 trial (NCT05822830).

Inclusion Criteria: * Have completed the SURMOUNT-5 study (NCT05822830; a trial of injectable tirzepatide \[Zepbound\] versus injectable semaglutide \[Wegovy\]) on study treatment Exclusion Criteria: * Have Type 1 Diabetes, Type 2 Diabetes, or any other types of diabetes, history of ketoacidosis, or hyperosmolar state/coma * Have a prior or planned surgical treatment for obesity * Have acute or chronic hepatitis * Have a history of acute or chronic pancreatitis